Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The successful incumbent for Launch Excellence is responsible for leading, planning, and managing US Commercial product launches at Mitsubishi Tanabe Pharma America, a cross-functional effort generally starting two years prior to launch and continuing after launch. The role involves coordinating teams, establishing strategy, and building processes. As a matrix organization, this role is especially cross-functional, with some of the other teams contributing to launch efforts being: Global Business Development, US Business Development, US Medical Affairs, US Regulatory, US Clinical, and US Commercial functions, such as Sales, Marketing, Market Access, and Analytics & Insights. Reporting to the Head/VP of Commercial, the individual will ensure coordination, data generation and alignment across functions, and act as the point person for Commercial leadership.   This position offers an extraordinary opportunity for individuals interested in building a US company with immediate opportunities in Neurology, CNS disorders and therapeutic areas with high unmet needs, while working with a cross functional team rich in exceptional talent.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.  The Manager Marketing Operations is responsible for leading and participating on multiple brands and commercial team projects.  This role will have oversight of the Commercial Budget, Leading Commercial Congress/Exhibits and community events for all brands.  Additionally, this role will lead the fulfillment side of the business.    The role offers an extraordinary opportunity for individuals interested in helping to grow a US company with immediate opportunities in the Orphan Drug and Specialty Markets, therapeutic areas with high unmet needs, while working with a fast pace cross functional team with exceptional talent. 

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account Specialist (NAS) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for ALS and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.    The NAS will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory.  The incumbent will be responsible for territory business planning and execution of key company initiatives.  In the execution of all duties, the NAS will adhere to company guidelines and demonstrate Integrity, Respect, Bravery, Collaboration and Persistence performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Senior Medical Director is responsible for the management of the Medical Safety Evaluation Office (MSE) of global products throughout the product lifecycle within the Global Drug Safety and Evaluation Center (GDSEC). He/she implements relevant policies to ensure the safety of the product in global development and post-marketing portfolio. The Senior Medical Director is also accountable for providing medical input to the assessment of the safety profile for each drug and appropriate and timely regulatory reporting of safety issues.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Director, Regulatory Affairs provides strategic global regulatory guidance to cross-functional project teams responsible for product development.  The successful candidate has a proven track record in the development of drugs, biologics/vaccines, and in the rare disease space.  In this role, the Director defines and implements regulatory strategies; works with cross-functional project teams to execute the agreed-upon strategies; supports departmental activities with regards to clinical trial conduct and regulatory submissions.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Business Operations and Transparency Reporting is responsible for (1) supporting transparency and reporting activities and (2) providing operational support to facilitate systems, workflows, and processes meeting transparency reporting and compliance requirements.  This role will also lead key compliance-driven operational initiatives, projects, and activities for supporting the field operations. This person will liaise between internal functions and external service providers to ensure operational success of business operations and transparency initiatives.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Field Medical Director (FMD) is a key leadership position within the US Medical Affairs organization. This person will be responsible for leading the western region Medical Science Director (MSD) team and will develop the strategic vision to ensure the implementation and development of territory plans, delegation of the appropriate resources to support the Scientific HealthCare Community, and ensuring the team is properly trained to be an effective partner to the field and home office. The individual will be part of the Medical Affairs Leadership Team and will report directly into the Vice President, Medical Affairs. The Field Medical Director will partner with the other Medical Affairs Leadership Team members to develop the appropriate strategy that will direct the overall strategic focus and tactical plans for the Medical Affairs department.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Senior Manager, Multichannel Marketing (MCM) will be responsible for the tactical design, execution and optimization of a fully integrated Multichannel Marketing plan. MCM includes all customer facing channels both offline and online -- websites, email, text/SMS, display, social media, search, video, webinars/webcasts, call centers (tele-sales/tele-support), etc.     The Senior MCM Manager will perform across commercialized products, as well as pipeline products.  Such activities include channel strategy recommendations, tactical launch plan and execution, followed by on-going post-launch updates and improvements. Incumbent will provide ongoing measurement and optimization at each stage. MCM efforts will be directed to multiple audiences (e.g., patients/consumers, caregivers, advocates, and HCPs).  

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Director of Patient Support at MTPA will hold a pivotal leadership role, with a significant focus on developing and implementing a cutting-edge patient support program. This role will be instrumental in ensuring that patients receive exceptional support and care throughout their journey with MTPA pharmaceutical products. The successful candidate will be a strategic thinker, an impassioned advocate for patients, and a transformative leader capable of inspiring a patient-centric culture throughout the organization.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Associate Director, Corporate Accounts will assume responsibility for driving product growth and business partnerships through optimal formulary access and reimbursement for assigned products within his/her national accounts. A critical success factor of this role will be demonstrating specific competencies through influence selling utilizing clinical knowledge, health economic and outcomes research, marketing resources, and leveraging and negotiating the value proposition which may include innovative contract strategy and rebating.  When negotiating, the incumbent will demonstrate strong financial stewardship for the company including a strategic plan for the ROI.  Additionally, the incumbent will contribute to high-level, cross-functional decisions working with Sales, Marketing, Advocacy, Contracting and other internal departments.  This is a field-based position.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Publications & Communications is a critical member of the Medical Affairs team and will be responsible for supporting the strategy, development and execution of internal and external tactics related to publications (abstracts, presentations, peer reviewed manuscripts), publication planning, advisory boards, and congress activities. This individual will work with key internal and external stakeholders to optimize the publication plans and projects including but not limited to abstracts, congress presentations, and manuscripts as well as working closely with medical directors in the planning and execution of advisory boards, support the interpretation of scientific/clinical data, lead the development of key publications and may be involved with medical writing of some publication projects. The Manager, Publications & Communications will manage engagement activities with external audiences, including vendors as well as with supporting communication with internal cross-functional partners. This role will directly report into the Executive Medical Director of Medical Affairs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Manager, Analytics & Insights is responsible for generating insights, managing market research projects, monitoring competition, finding insights in data, and contributing to forecasts for existing and future brands at Mitsubishi Tanabe Pharma America.  The position sits within Commercial and reports to the Director, Commercial Analytics & Insights.   This position offers an extraordinary opportunity for individuals interested in growing in a nimble, agile company and contributing to vital initiatives within the Commercial organization, where our focus is therapeutic areas with high unmet needs.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Associate Director, Business & Research Strategy, develops, proposes, and executes global product and launch strategy of late-stage clinical development programs including but not limited to launch sequencing strategy, under oversight by the Global Product Leader, collaborating with relevant internal stakeholders to maximize the value of late-stage clinical development programs across all possible indications in a global manner.   To accomplish this goal, the incumbent facilitates internal discussion with experience and expertise in global product launch, product R&D and management, market research, and profit/loss analysis.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.  The Manager, Patient Access will support implementation of reimbursement education and distribution service plans to achieve product and corporate revenue and reimbursement objectives, meet customer needs, and help develop overall commercial excellence.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account Specialist (NAS) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for ALS and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.   The NAS will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS will adhere to company guidelines and demonstrate honesty, integrity, trust, respect, and accountability, performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Neurology Account Specialist (NAS) will be responsible for meeting and/or exceeding sales goals in an assigned territory by developing, implementing, and executing an integrated territory business plan encompassing key customer targets. The incumbent will demonstrate subject matter expertise concerning scientific and clinical information for ALS and take a customer-focused approach to engage customers in clinically relevant discussion utilizing approved materials.   The NAS will effectively analyze sales data to identify opportunities for business growth or areas of concern within the assigned territory. The incumbent will be responsible for territory business planning and execution of key company initiatives. In the execution of all duties, the NAS will adhere to company guidelines and demonstrate honesty, integrity, trust, respect, and accountability, performing all responsibilities in accordance with company policies and procedures and applicable state and federal rules and regulations.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Manager, Market Access facilitates positive momentum towards launching pipeline products within the Market Access department by drawing on a thorough understanding of each Market Access function (Trade, Patient Access, Hub Services, Government Affairs and Corporate Accounts). The Manager, Market Access builds relationships throughout the organization, coordinates activities across multiple business divisions of the company, and develops key materials for internal and external use, including: channel strategy, marketing pieces (e.g., CADs, MPAs, Trade, Government Affairs), internal and customer-facing presentations, and training materials. This role is a critical contributor in the pre and post launch period for market conditioning and launch execution. The Manager, Market Access will report directly into the Director, Trade Channel Strategy. The Manager, Market Access will be responsible for in-line ALS products that are already in market as well pre-launch activities of Parkinson’s Disease pipeline products.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Senior Marketing Manager will help develop and execute integrated marketing plans and tactics. Initially the work will focus on the promotion of Radicava ORS as well as the launch of ND0612. The Senior Marketing Manager will perform across the full product life cycle: pre-launch activities, marketing material creation, market research, tactical planning, patient education execution, digital marketing, and will perform duties with a high degree of independence. Marketing efforts will be directed to multiple audiences (e.g., patients/consumers, caregivers, advocates, and other stakeholders). As a senior-level marketing manager, the incumbent will be assigned marketing projects and programs with a higher level of complexity as compared to other marketing managers. The role requires close collaboration with other marketing staff and may require some oversight and on-the-job training of less senior colleagues in order to continually develop and strengthen team capabilities. The role also includes collaboration with other Mitsubishi Tanabe Pharma America functional areas as well as patients, caregivers, advocates, HCPs/KOLs, creative agencies and other external partners.   This position offers an extraordinary opportunity for individuals interested in building a US company with immediate opportunities in Neurology, CNS disorders and therapeutic areas with high unmet needs, while working with a cross-functional team rich in exceptional talent. It also offers a unique opportunity to contribute to a budding company culture and drive innovative approaches to healthcare.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.    The Associate Director, HCP Marketing is responsible for implementing tactics and strategies for all promoted Mitsubishi Tanabe Pharma America (MTPA) products to HCPs. Incumbent will drive projects supporting the brand plan on HCP strategies.   They will organize meetings to discuss and agree on the core strategies and tactics for each brand, track implementation of key activities for each MTPA product in the critical commercial aspects of promoting each product in their respective market. This will include: HCP marketing material creation, market / competitive analysis, marketing plan, strategic/tactical launch process execution, followed by lifecycle planning. To perform successfully in the role, the incumbent will draw heavily on his/her prior pharmaceutical industry experience, including in-depth experience with pharmaceutical marketing, Neurology, CNS or Rare/Orphan Drugs. This role will also lead or support a variety of specific marketing or cross functional projects as needed to help the HCP Marketing team. The incumbent will have significant involvement with senior leadership, given the prominence and importance of brand planning for Mitsubishi Tanabe Pharma America. The Associate Director, Marketing will collaborate closely with other Mitsubishi Tanabe affiliates/functional areas as well as HCPs/KOLs, patient advocacy groups, creative agencies and other external partners to ensure successful commercialization.   This position offers an extraordinary opportunity for individuals interested in building a US company with immediate opportunities in Neurology, CNS disorders and therapeutic areas with high unmet needs, while working with a cross functional team rich in exceptional talent.

Entrepreneurial Spirit, Rooted in Tradition. Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a U.S. subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC) in Japan, which touts a storied reputation more than 300 years in the making. Our parent company - one of Japan’s most respected - is a research-driven pharmaceutical company that has tirelessly pursued medical breakthroughs with global reach. MTPC has discovered and produced several first-in-class medicines for serious diseases, including multiple sclerosis (MS), diabetes mellitus (DM), and amyotrophic lateral sclerosis (ALS).   MTPA is rapidly expanding its operations across all functional areas. MTPA’s commitment to patients and their communities continues with a robust late-stage pipeline of investigational treatments for difficult-to-treat diseases and commercializing products with significant unmet medical needs in North American markets.  In the United States, MTPA launched rare diseases treatments including RADICAVA® (edaravone) injectables in 2017, EXSERVAN™ (riluzole) oral film in 2021, and RADICAVA® (edaravone) oral suspension in 2022.  The company handles research, clinical development, sales, marketing, medical affairs, and business development functions.  MTPA is dedicated to improving the treatment environment for those with debilitating diseases, researching on real-world evidence, and creating hope for all facing illness.   The Senior Director, Distribution, will build the team and focus on strategy to support the launch and life cycle management of our lead Parkinson and ALS therapies and future products in the United States. The primary responsibility of the Senior Director Distribution is to develop and implement the distribution strategies across the specialty businesses. This includes specialty pharmacies, distributors and all channels that would handle any present or future MTPA products. This person will have an intimate knowledge of the distribution systems from all aspects including durable medical equipment. This person will also need to be experienced at leading teams that work directly and indirectly with our specialty vendors. In doing so they will need excellent analytical skills to understand gaps and implement solutions.  These skills will contribute to the better overall health outcomes for patients. The ability to work cross functionally with supply chain, brand teams, sales and customer facing teams will be imperative. Initially the focus will be on Neuroderm and ORS.